<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated a novel alemtuzumab-based conditioning regimen in HSCT for acquired severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) </plain></SENT>
<SENT sid="1" pm="."><plain>In a multicenter retrospective study, 50 patients received transplants from matched sibling donors (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e>; n = 21) and unrelated donors (UD; n = 29), using fludarabine 30 mg/m² for 4 days, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 300 mg/m² for 4 days, and alemtuzumab median total dose of 60 mg (range:40-100 mg) </plain></SENT>
<SENT sid="2" pm="."><plain>Median age was 35 years (range 8-62) </plain></SENT>
<SENT sid="3" pm="."><plain>Overall survival at 2 years was 95% ± 5% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> and 83% for UD HSCT (p 0.34) </plain></SENT>
<SENT sid="4" pm="."><plain>Cumulative incidence of graft failure was 9.5% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> and 14.5% for UD HSCT </plain></SENT>
<SENT sid="5" pm="."><plain>Full-donor chimerism (<z:chebi fb="17" ids="38848">FDC</z:chebi>) in unfractionated peripheral blood was 42%; no patient achieved CD3 <z:chebi fb="17" ids="38848">FDC</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GVHD was observed in only 13.5% patients (<z:hpo ids='HP_0000001'>all</z:hpo> grade I-II) and only 2 patients (4%) developed <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="7" pm="."><plain>A low incidence of <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> was seen </plain></SENT>
<SENT sid="8" pm="."><plain>Factors influencing overall survival were HSCT comorbidity 2-year index (92% with score 0-1 vs 42% with score ≥ 2, P &lt; .001) and age (92% for age &lt; 50 years vs 71% ≥ 50 years, P &lt; .001) </plain></SENT>
<SENT sid="9" pm="."><plain>Our data suggest that the use of an alemtuzumab-based HSCT regimen for SAA results in durable engraftment with a low incidence of <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
</text></document>